TCGA-77-A5G8-01B-11R-A27Q-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.370
- APICAL_SURFACE+0.250
- HEDGEHOG_SIGNALING+0.250
- HYPOXIA+0.230
- SPERMATOGENESIS+0.200
- COAGULATION+0.190
- MYOGENESIS+0.190
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.170
- ESTROGEN_RESPONSE_LATE+0.150
- PANCREAS_BETA_CELLS+0.150
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- TGF_BETA_SIGNALING-0.490
- PROTEIN_SECRETION-0.440
- INTERFERON_GAMMA_RESPONSE-0.420
- DNA_REPAIR-0.390
- MITOTIC_SPINDLE-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.310
- MYC_TARGETS_V1-0.300
- PEROXISOME-0.290
- ANDROGEN_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797259 | — | cohortSC | 0.867 |
| 2 | SRR26320080 | — | — | 0.819 |
| 3 | R114 | — | — | 0.809 |
| 4 | GSM5359442 | — | — | 0.800 |
| 5 | BS_YE1MAQYJ | EPN | EPN Tumor | 0.790 |
| 6 | SRR4296064 | — | cohortA1 | 0.788 |
| 7 | SRR1352975 | GTEX | — | 0.783 |
| 8 | SRR6013476 | — | cohortSQ1 | 0.780 |
| 9 | TCGA-O2-A52W-01A-11R-A26W-07 | — | cohortSQ1 | 0.776 |
| 10 | SRR1083100 | GTEX | — | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |